Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators
AssigneeEli Lilly and Company
InventorsKonstantinos Gavardinas, Prabhakar Kondaji Jadhav, Douglas Richard Stack, Ian Roger Clemens
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of the Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
Claims26
A compound of the formula:
- wherein,
- R1 represents CN;
- R2 represents halo, halo(C1-C4)alkyl, or (C1-C4)alkyl;
- R3 represents H or (C1-C4)alkyl;
- R4 represents an aryl, heterocycle, or benzofused heterocycle, each optionally substituted with 1-2 substituents independently selected from the group consisting of:
- (a) halo;
- (b) (C1-C4)alkyl;
- (c) (C1-C4)alkoxy;
- (d) halo(C1-C4)alkyl;
- (e) halo(C1-C4)alkoxy;
- (f) SR7;
- (g) SO2R8;
- (h) amino;
- (i) NH—(C1-C4)alkylamine;
- (j) N,N—(C1-C4)dialkylamine;
- (k) NHCOR9;
- or
- (l) NHSO2R10;
- R4a represents hydrogen or methyl;
- R5 represents H, OH, CH2OH, halo, or (C1-C4)alkyl;
- R6 represents H, OH, or (C1-C4)alkyl, provided that when R5 and R6 each represent OH, they are not bound to the same carbon atom;
- and
- R7 through R10 each independently represent at each occurrence (C1-C4)alkyl, or a pharmaceutically acceptable salt thereof
2-4. (canceled)
(canceled)
(canceled)
21-22. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.